Cargando…
PEG-ing down (and preventing?) the cause of pegloticase failure
Pegloticase is a powerful but underutilized weapon in the rheumatologist’s armamentarium. The drug’s immunogenicity leads to neutralizing antibody formation and rapid loss of efficacy in roughly one-half of all patients, which remains an impediment to broader use. New data, however, suggest that dru...
Autor principal: | Abeles, Aryeh M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4060209/ https://www.ncbi.nlm.nih.gov/pubmed/25142440 http://dx.doi.org/10.1186/ar4572 |
Ejemplares similares
-
Febuxostat and the Black Box Blues
por: Abeles, Aryeh M., et al.
Publicado: (2019) -
New advances in the treatment of gout: review of pegloticase
por: Reinders, Mattheus K, et al.
Publicado: (2010) -
Critical appraisal of the role of pegloticase in the management of gout
por: Ea, Hang-Korng, et al.
Publicado: (2012) -
Pegloticase in Uncontrolled Gout: The Infusion Nurse Perspective
por: Baxter, Britni, et al.
Publicado: (2023) -
TRP-ing Down the Path to Insulin Secretion
por: MacDonald, Patrick E.
Publicado: (2011)